MedTrace Logo

Roxadustat for Anemia in Patients With CKD

NCT04502537 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-01-22

No results posted yet for this study

Summary

A number of RCT studies have shown the safety and effectiveness of oral Roxadustat in the treatment of renal anemia, but there is a lack of evidence from cohort studies. A prospective cohort study is planed to conduct to evaluate the efficacy and safety of Roxadustat for renal anemia in the real world.

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

DRUG

Roxadustat

Oral

DRUG

erythropoietin

injection

Sponsors & Collaborators

  • Shenzhen Second People's Hospital

    lead OTHER

Principal Investigators

  • Yuan Cheng, Dr. · Shenzhen Second People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-06-30
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04502537 on ClinicalTrials.gov